Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells

Breast Cancer Research and Treatment

Volumn 149, Issue 3, 2015, Pages 715-726

  Hole, Stine ^a   Pedersen, Astrid M ^a   Lykkesfeldt, Anne E ^a   Yde, Christina W ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Aromatase inhibitor resistance; Aurora kinases; Breast cancer; Cell cycle; Kinase inhibitors

Indexed keywords

ALISERTIB; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; AURORA A KINASE; AURORA B KINASE; BARASERTIB; DANUSERTIB; FULVESTRANT; JNJ 7706621; UNCLASSIFIED DRUG; 2-((3-((4-((5-(2-((3-FLUOROPHENYL)AMINO)-2-OXOETHYL)-1H-PYRAZOL-3-YL)AMINO)QUINAZOLIN-7-YL)OXY)PROPYL)(ETHYL)AMINO)ETHYL DIHYDROGEN PHOSPHATE; AURKA PROTEIN, HUMAN; AURKB PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; JNJ-7706621; MOLECULAR LIBRARY; ORGANOPHOSPHATE; QUINAZOLINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MOLECULAR DYNAMICS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION; ADMINISTRATION AND DOSAGE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; MCF 7 CELL LINE; MOLECULAR LIBRARY; PATHOLOGY;

AROMATASE INHIBITORS; AURORA KINASE A; AURORA KINASE B; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MCF-7 CELLS; ORGANOPHOSPHATES; QUINAZOLINES; SMALL MOLECULE LIBRARIES; TRIAZOLES;

EID: 84922594316     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3284-8     Document Type: Article

References (27)

1. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A (2011) Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol 125(1–2):13–22
2. Ghosh D, Griswold J, Erman M, Pangborn W (2009) Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 457(7226):219–223
3. Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M (2002) Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 81(4–5):333–341
4. Kazi AA, Gilani RA, Schech AJ, Chumsri S, Sabnis G, Shah P, Goloubeva O, Kronsberg S, Brodie AH (2014) Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. Breast Cancer Res 16(1):R15
5. Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, Chen S (2008) Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 68(12):4910–4918
6. Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM (2014) Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget 5(19):9049–9064
7. Beaver JA, Park BH (2012) The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 8(6):651–657
8. Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W (2010) Aurora kinase inhibitors–rising stars in cancer therapeutics? Mol Cancer Ther 9(2):268–278
9. Goldenson B, Crispino JD (2014) The aurora kinases in cell cycle and leukemia. Oncogene. doi:10.1038/onc.2014.14
10. Nair JS, Ho AL, Tse AN, Coward J, Cheema H, Ambrosini G, Keen N, Schwartz GK (2009) Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. Mol Biol Cell 20(8):2218–2228
11. Vader G, Lens SMA (2008) The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 1786(1):60–72
12. Thrane S, Pedersen AM, Thomsen MBH, Kirkegaard T, Rasmussen BB, Duun-Henriksen AK, Lænkholm AV, Bak M, Lykkesfeldt AE, Yde CW (2014) A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in anti-estrogen-resistant breast cancer cells. Oncogene. doi:10.1038/onc.2014.351
13. Sonne-Hansen K, Lykkesfeldt AE (2005) Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. J Steroid Biochem Mol Biol 93(1):25–34
14. Hole S, Pedersen AM, Hansen SK, Lundqvist J, Yde CW, Lykkesfeldt AE (2015) New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. Int J Oncol. doi:10.3892/ijo.2015.2850
15. Briand P, Lykkesfeldt AE (1984) Effect of estrogen and antiestrogen on the human breast cancer cell-line MCF-7 adapted to growth at low serum concentration. Cancer Res 44(3):1114–1119
16. Lykkesfeldt AE, Madsen MW, Briand P (1994) Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 54(6):1587–1597
17. Lundholt BK, Briand P, Lykkesfeldt AE (2001) Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat 67(3):199–214
18. Pedersen AM, Thrane S, Lykkesfeldt AE, Yde CW (2014) Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor alpha. Int J Oncol 45(5):2167–2175
19. Yde CW, Olsen BB, Meek D, Watanabe N, Guerra B (2008) The regulatory beta-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis. Oncogene 27(37):4986–4997
20. Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, Yeung SC, Lee MH (2010) Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer 9:42
21. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF, Sells TB (2011) Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 17(24):7614–7624
22. Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, Rusconi L, Storici P, Zugnoni P, Arrigoni C, Soncini C, Alli C, Patton V, Marsiglio A, Ballinari D, Pesenti E, Fancelli D, Moll J (2007) PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 6(12 Pt 1):3158–3168
23. Scrittori L, Skoufias DA, Hans F, Gerson V, Sassone-Corsi P, Dimitrov S, Margolis RL (2005) A small C-terminal sequence of Aurora B is responsible for localization and function. Mol Biol Cell 16(1):292–305
24. Lonning PE, Eikesdal HP (2013) Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocr Relat Cancer 20(4):R183–R201
25. Zheng XQ, Guo JP, Yang H, Kanai M, He LL, Li YY, Koomen JM, Minton S, Gao M, Ren XB, Coppola D, Cheng JQ (2013) Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERalpha in breast cancer. Oncogene. doi:10.1038/onc.2013.444
26. Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS, Yde CW (2013) Estrogen receptor alpha is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat 139(1):71–80
27. Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, Gonzalez-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL (2011) ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 1(4):338–351